Neurocalcin-delta: a potential memory-related factor in hippocampus of obese rats induced by high-fat diet.

Ma, Weiwei; Ding, Bingjie; Yuan, Linhong; Zhao, Lei; Yu, Huanling; Xi, Yuandi; Xiao, Rong

doi:10.4314/ahs.v17i4.32

Cited by 12 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The gene NCALD encoding neurocalcin delta (NCALD), which belongs to the subfamily of helix‐loop‐helix calcium‐binding proteins 8 and often plays roles in diet‐induced obesity, 9 spinal muscular atrophy, 10 neurocognitive disabilities, 11 and other diseases. The association of NCALD with cancer is obscure; few studies have implicated this gene in autophagy, the S phase of the cell cycle, transduction, apoptosis, and cell cycle progression in several cancers 12,13 .…”

Section: Introductionmentioning

confidence: 99%

NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer

Dong

Yin

Zhu

et al. 2020

J of Cellular Biochemistry

View full text Add to dashboard Cite

Drug resistance, an impenetrable barrier in the treatment of ovarian cancer (OC), is often associated with poor outcomes. Hence, it is urgent to discover new factors controlling drug resistance and survival. The association between neurocalcin delta (NCALD) and cancer drug resistance is poorly understood. Here, we reveal that NCALD messenger RNA expression, probably regulated by DNA methylation and microRNAs, was significantly downregulated in at least three independent microarrays covering 633 ovarian carcinomas and 16 normal controls, which includes the Cancer Genome Atlas (TCGA) ovarian cohort. In the sub‐groups of the TCGA cohort, NCALD was suppressed in 90 platinum‐resistant tissues vs in 197 sensitive tissues. It is consistent with the quantitative reverse transcription polymerase chain reaction results revealing gene downregulation in carboplatin‐resistant SKOV3 and HeyA8 OC cells as compared with that in controls. Low expression of NCALD predicted poor overall survival (OS) in sub‐groups of 1656 patients, progression‐free survival (PFS) in 1435 patients, and post‐progression survival (PPS) in 782 patients according to Kaplan‐Meier plotter covering 1815 OC patients. Comprehensive bioinformatic analyses strongly implicated NCALD in the regulation of drug resistance, probably via competing for endogenous RNA (ceRNA) interactions with CX3CL1 and tumor immune‐microenvironment. NCALD acted as a ceRNA for CX3CL1 in 21 different cancers includes OC according to Starbase. These two genes negatively correlated with tumor purity and positively correlated with infiltration levels of neutrophils and dendritic cells in OC. The combined low expression of NCALD and CX3CL1 showed better prognosis potential for OS, PFS, and PPS in the 1815 OC patients than any of the individually tested genes. In summary, NCALD acts as a ceRNA for CX3CL1, and its downregulation may affect drug resistance and prognosis in OC. Thus, NCALD could be a new therapeutic target for anticancer therapy and a new biomarker for survival prediction in OC.

show abstract

Section: Introductionmentioning

confidence: 99%

NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer

Dong

Yin

Zhu

et al. 2020

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…(2019) reported that Ncald KO impaired neurogenesis in adult mice, while Ncald heterozygous mice did not exhibit significant changes. Additionally, Ncald was downregulated in the obesity-induced memory impairment animal model ( Ma et al ., 2017 ). Thus, the study suggested that Ncald might play important roles in memory.…”

Section: Discussionmentioning

confidence: 99%

Gene Expression Profiling in the Striatum of Per2 KO Mice Exhibiting More Vulnerable Responses against Methamphetamine

Kim

Jeon

Custodio

et al. 2021

Biomolecules & Therapeutics

View full text Add to dashboard Cite

Drug addiction influences most communities directly or indirectly. Increasing studies have reported the relationship between circadian-related genes and drug addiction. Per2 disrupted mice exhibited more vulnerable behavioral responses against some drugs including methamphetamine (METH). However, its roles and mechanisms are still not clear. Transcriptional profiling analysis in Per2 knockout (KO) mice may provide a valuable tool to identify potential genetic involvement and pathways in enhanced behavioral responses against drugs. To explore the potential genetic involvement, we examined common differentially expressed genes (DEGs) in the striatum of drug naïve Per2 KO/wild-type (WT) mice, and before/after METH treatment in Per2 KO mice, but not in WT mice. We selected 9 common DEGs ( Ncald , Cpa6 , Pklr , Ttc29 , Cbr2 , Egr2 , Prg4 , Lcn2 , and Camsap2 ) based on literature research. Among the common DEGs, Ncald , Cpa6 , Pklr , and Ttc29 showed higher expression levels in drug naïve Per2 KO mice than in WT mice, while they were downregulated in Per2 KO mice after METH treatment. In contrast, Cbr2 , Egr2 , Prg4 , Lcn2 , and Camsap2 exhibited lower expression levels in drug naïve Per2 KO mice than in WT mice, while they were upregulated after METH treatment in Per2 KO mice. qRT-PCR analyses validated the expression patterns of 9 target genes before/after METH treatment in Per2 KO and WT mice. Although further research is required to deeply understand the relationship and roles of the 9 target genes in drug addiction, the findings from the present study indicate that the target genes might play important roles in drug addiction.

show abstract

“…It involves in neuronal diseases and nutritional metabolic diseases. Such as spinal muscular atrophy [16][17][18], epilepsy [19,20], depression [21], obesity [22], diabetes [23] and celiac disease [24]. Currently, there is little research on NCALD in ovarian cancer.…”

Section: Discussionmentioning

confidence: 99%

Low expression of NCALD is associated with chemotherapy resistance and poor prognosis in epithelial ovarian cancer

Feng

2020

J Ovarian Res

View full text Add to dashboard Cite

Background: Low expression of NCALD(neurocalcin delta) in peripheral blood of ovarian cancer patients predicts poor prognosis. However, the molecular mechanism of NCALD in ovarian cancer and its relationship with chemotherapy outcomes is unclear. The aim of this study was to investigate the potential signaling pathways of NCALD and to evaluate its ability to predict chemotherapy outcomes and prognosis. Methods: High-throughput RNA sequencing data were downloaded from TCGA. GSEA explored the potential signaling pathways of NCALD. The expression of NCALD in chemotherapy sensitive and chemotherapy resistant ovarian cancer patients was detected by TCGA data and clinical samples. ROC analysis confirmed the ability of NCALD to predict chemotherapy outcomes. The association between NCALD expression and prognosis in ovarian cancer patients was assessed using Kaplan-Meier plotter. Results: In patients with NCALD overexpression, genes expression related to ERK1 / 2 signaling pathway, NF-kappaB signaling pathway, TGF-β signaling pathway and immune response pathway was increased, especially ERK1 / 2 signaling pathway. The expression of NCALD in chemoresistant patients was significantly lower than chemosensitive patients. In TCGA data and immunohistochemical samples, the AUC of NCALD expression predicting chemotherapy outcome was 0.59 and 0.64, respectively. In clinical samples, low expression of NCALD was associated with poor OS and PFS. Conclusions: NCALD may activate the ERK1 / 2 signaling pathway in ovarian cancer. As a new biomarker of chemotherapy sensitivity, NCALD was significantly down-regulated in chemotherapy resistance ovarian cancer patients. Low expression of NCALD in ovarian cancer is associated with poor OS and PFS. In the future, further research will be needed on the potential mechanism and clinical application value of NCALD in ovarian cancer.

show abstract

Neurocalcin-delta: a potential memory-related factor in hippocampus of obese rats induced by high-fat diet.

Cited by 12 publications

References 34 publications

NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer

NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer

Gene Expression Profiling in the Striatum of Per2 KO Mice Exhibiting More Vulnerable Responses against Methamphetamine

Low expression of NCALD is associated with chemotherapy resistance and poor prognosis in epithelial ovarian cancer

Contact Info

Product

Resources

About